comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 01:07:45 - browse：7984

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Lack of darker skin in textbooks, journals harms patients of color

knowledge

WSS

Why you get paid to donate plasma but not blood

When prostate cancer spreads, where it goes matters

Helping hospitals and community health centers plan for resilience

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Study: Hearing aids may slow cognitive decline in those at risk

Arc Institute generative AI designs new CRISPR systems

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Sports medicine is finally prioritizing gender equality

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Supreme Court strikes down use of affirmative action

Why you get paid to donate plasma but not blood

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

ChatGPT in medicine: STAT answers readers' burning questions

Cytokinetics CEO stresses company can launch heart drug on its own

Medical records are filled with copy

NVIDIA and Google execs on the future of AI and drug discovery

knowledge

US soldier in North Korean custody after crossing DMZ line

Criminal prosecution for violating HIPAA: an emerging threat

Twill hunts for pharma partner to market its depression app

NVIDIA and Google execs on the future of AI and drug discovery

US soldier in North Korean custody after crossing DMZ line

UK homeowners get some respite as inflation falls by more than anticipated to a 15

focus

knowledge

knowledge

Wikipedia